back to Canada directory
canada clinical guidance

Lyme disease

A Canadian clinical summary of lyme disease, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Lyme disease: For health professionals. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:PHAC Lyme

Source-attributed clinical priorities

  • Diagnose classic erythema migrans clinically and use two-tier serology for appropriate later manifestations, recognizing early false negatives.
  • Select treatment by manifestation, age and pregnancy and report according to provincial or territorial requirements.
sources for this section:PHAC Lyme

Practical assessment and management workflow

1
Record tick location, attachment estimate, removal date, travel and onset of rash, neurologic, cardiac or joint symptoms.
2
Diagnose a typical expanding erythema migrans lesion clinically and test only when the syndrome and timing support it.
3
Use two-tier serology for appropriate disseminated presentations and interpret early negatives cautiously.
4
Select treatment by manifestation and arrange follow-up for objective persistent or new features.
sources for this section:PHAC Lyme

Safety, red flags and urgent escalation

  • Syncope, high-grade heart block, meningitis or significant cranial or radicular disease needs urgent specialist care.
  • Do not use unvalidated commercial tests or prolonged antibiotics for nonspecific symptoms without evidence of active infection.
  • Follow provincial public-health reporting and tick-submission advice.
sources for this section:PHAC Lyme

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:PHAC Lyme

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:PHAC Lyme

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Public Health Agency of CanadaLyme disease: For health professionalsaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.